Medicine in China

Hearts Connect along the Silk Road, International Voluntary Service Seminar Held in Nanjing

Retrieved on: 
Tuesday, December 26, 2023
Civic, Result, Congress, Silk Road, Practice, International volunteering, Communication, Climate change, Economic development, UNDP, Amity Foundation, Normal school, Xinhua News Agency, Sustainable development, Beijing Normal University, Speech, Civilization, Chinese culture, Generation Z, Non-governmental organization, Path, Belt and Road Initiative, University of Birmingham, Collection, Rural development, Ventricular septal defect, Volunteering, Medicine in China, Tourism

Nanjing, China--(Newsfile Corp. - December 26, 2023) - On December 19, the "Hearts Connect along the Silk Road" International Volunteer Service Seminar, organized by the International Volunteer Service Working Committee and hosted by Office of Nanjing Municipal Civic Enhancement Committee, took place in Nanjing, known as the literary hub of the world.

Key Points: 
  • Nanjing, China--(Newsfile Corp. - December 26, 2023) - On December 19, the "Hearts Connect along the Silk Road" International Volunteer Service Seminar, organized by the International Volunteer Service Working Committee and hosted by Office of Nanjing Municipal Civic Enhancement Committee, took place in Nanjing, known as the literary hub of the world.
  • Experts, scholars, and youth representatives from international institutions, research institutes, and NGOs in the field of volunteer service gathered in the city to exchange experiences and achievements in promoting sustainable development through voluntary service.
  • She highlighted the positive impact of international volunteer service in enhancing mutual understanding and communication between China and other nations.
  • Zhu Jingfang, Deputy Director of the International Volunteer Service Working Committee, stressed that international volunteer service is a crucial means for countries to engage in global governance, shape their international image, and enhance international influence.

Hearts Connect along the Silk Road, International Voluntary Service Seminar Held in Nanjing

Retrieved on: 
Tuesday, December 26, 2023
Civic, Civilization, Medicine in China, Sustainable development, Result, Amity Foundation, Xinhua News Agency, Non-governmental organization, News, International volunteering, Communication, Ventricular septal defect, Economic development, University of Birmingham, UNDP, Rural development, Climate change, Hermitage Volunteer Service, Finance, Path, Collection, Volunteering, Beijing Normal University, Normal school, Generation Z, Belt and Road Initiative, Speech, Congress, Silk Road, Practice, Tourism, Tham Luang Nang Non

NANJING, CHINA - Media OutReach Newswire - 26 December 2023 - On December 19, the "Hearts Connect along the Silk Road" International Volunteer Service Seminar, organized by the International Volunteer Service Working Committee and hosted by Office of Nanjing Municipal Civic Enhancement Committee, took place in Nanjing, known as the literary hub of the world.

Key Points: 
  • NANJING, CHINA - Media OutReach Newswire - 26 December 2023 - On December 19, the "Hearts Connect along the Silk Road" International Volunteer Service Seminar, organized by the International Volunteer Service Working Committee and hosted by Office of Nanjing Municipal Civic Enhancement Committee, took place in Nanjing, known as the literary hub of the world.
  • Duan Guiqing, Deputy Secretary-General of the China Volunteer Service Federation, emphasized the crucial role of voluntary service in building a community with a shared future for humanity.
  • She highlighted the positive impact of international volunteer service in enhancing mutual understanding and communication between China and other nations.
  • Zhu Jingfang, Deputy Director of the International Volunteer Service Working Committee, stressed that international volunteer service is a crucial means for countries to engage in global governance, shape their international image, and enhance international influence.

Suzhou OSAI Biopharma Announces Positive Phase III Clinical Trial Results for Lactobacillus Crispatus Live Bacteria Capsule, Significantly Reducing Recurrence of Gynecological Infections

Retrieved on: 
Tuesday, December 12, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Safety, Piper LBP, Incidence, Vaginitis, Gynaecology, Patient, Infection, Bacterial vaginosis, Medicine in China, MD, Phase, LBP, Obstetrics, Recurrence, BV, Therapure BioPharma Inc, Pharmaceutical industry

Suzhou OSAI Biopharma, Inc., a biopharmaceutical company focused on developing live biotherapeutic products (LBPs), today announced that its Phase III clinical trial of vaginal L. crispatus live bacteria capsule (Lc262-1) has successfully met its primary and secondary endpoints.

Key Points: 
  • Suzhou OSAI Biopharma, Inc., a biopharmaceutical company focused on developing live biotherapeutic products (LBPs), today announced that its Phase III clinical trial of vaginal L. crispatus live bacteria capsule (Lc262-1) has successfully met its primary and secondary endpoints.
  • The Phase III study was a multicenter, randomized, double-blind, placebo-controlled trial that enrolled 320 patients with bacterial vaginosis (BV).
  • After receiving seven days of oral metronidazole and vaginal LBP/placebo combination therapy, the cured patients were followed up for three months.
  • “This Phase III clinical trial is the first registrational Phase III clinical trial globally to evaluate the efficacy of L. crispatus in reducing BV recurrence under a rigorous clinical design.

Impulse Dynamics Announces 100th Implant Milestone in China for CCM® Therapy

Retrieved on: 
Wednesday, November 16, 2022
Tao, Marketing, Blood, Cardiac muscle, Heart, Muscle tissue, Medicine, Forward problem of electrocardiology, Heart rate, Chinese Academy of Medical Sciences COVID-19 vaccine, Safety, Physician, Patient, Heart failure, National Center for Health Research, Chinese Medical Doctor Association, MD, Mathematical optimization, CCM, News, Internal medicine, Chinese Academy of Fishery Sciences, Death, Degenerative disease, Research, Quality of life, Hope, Medicine in China, FDA, Medical device, Pharmaceutical industry

It is quite a coincidental milestone for us that the 10th patient implanted in our center also happened to be the 100th patient treated in China.

Key Points: 
  • It is quite a coincidental milestone for us that the 10th patient implanted in our center also happened to be the 100th patient treated in China.
  • I have paid very close attention to CCM therapy for more than 20 years now, but it wasnt until recently we could clinically apply this technology.
  • All the CCM patients in our center improved both symptomatically and on various objective indicators, which made both us and our patients very happy.
  • CCM therapy was approved in China late last year, and the first implant in the country was announced on November 1, 2021.

CCC and Chinese Medical Association Publishing House Partner to Provide Global Licensing Solution for CMA Articles

Retrieved on: 
Tuesday, August 2, 2022
Software, Research, General Health, Professional Services, Technology, Publishing, Science, Legal, Communications, Other Technology, Other Science, Health, Knowledge, CCC, Copyright Clearance Center, Chinese Medical Journal, The National Medical Journal of India, Rodionov Publishing House, Research, Solution, Software, House, Collection, Geography, International relations, Medicine in China, Organization, 2019 UEFA European Under-21 Championship squads, CMA, Publishing, International, Information management, Workflow, Medical device, Management

CMAPH is the leading publisher of medical journals in China, including the prestigious Chinese Medical Journal and National Medical Journal of China.

Key Points: 
  • CMAPH is the leading publisher of medical journals in China, including the prestigious Chinese Medical Journal and National Medical Journal of China.
  • This arrangement with CCC enables wider dissemination of and global access to Chinese medical articles.
  • International medical researchers now have seamless access to use and reproduce Chinese research in the pursuit of medical innovations.
  • The Chinese Medical Association (CMA) Publishing House is society-affiliated medical publisher, which aims to publish national journals in general medicine and various specialties.

Zhongchao Inc. Announces its MDMOOC Platform Launched Disease Prevention and Distribution Quality Management Course

Retrieved on: 
Monday, June 13, 2022
National Center for Immunization and Respiratory Diseases, Vaccination, Coronavirus, Goal, Company, Neoplasm, Evaluation, Medicine in China, National Immunization Technical Advisory Group, Forward-looking statement, WHO, Growth, Cayman Islands, Private Securities Litigation Reform Act, Technology, Review, NASDAQ, SEC, Association, Public health, Efficiency, Degenerative disease, WeChat, Immunization, Course, Committee, Medicine, Vaccine, Pharmaceutical industry, Public relations, PRC

SHANGHAI, June 13, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today announced its MDMOOC platform launched online training course (the "Course") titled "Disease Prevention and Distribution Quality Management," to staffs (the "Staffs") in various departments for diseases control and prevention, in order to improve their skillsets and efficiency in vaccination management as well as diseases control and prevention.

Key Points: 
  • SHANGHAI, June 13, 2022 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patient management service, today announced its MDMOOC platform launched online training course (the "Course") titled "Disease Prevention and Distribution Quality Management," to staffs (the "Staffs") in various departments for diseases control and prevention, in order to improve their skillsets and efficiency in vaccination management as well as diseases control and prevention.
  • The Course was launched in April 2022 and is expected to provide trainings for up to 20,000 people.
  • Participants can access the Course through MDMOOC's website, the Company's WeChat public account, and the Company's WeChat mini program platform.
  • The Company undertakes no obligation to publicly revise these forwardlooking statements to reflect events or circumstances that arise after the date hereof.

Luye Pharma Releases Top-Line Results from a Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release Tablets

Retrieved on: 
Thursday, December 23, 2021
NDA, Conference, Medicine in China, New Drug Application, Patient, LY03005, Somnolence, Phase, Major depressive disorder, SNDRI, Reuptake, NCE, MDD, Hamilton Rating Scale for Depression, Safety, Pharmaceutical industry, New chemical entity

CHONGQING, China, Dec. 23, 2021 /PRNewswire/ --Luye Pharma Group today released the encouraging top-line results from a Phase II clinical trial of its new antidepressant, Ansofaxine Hydrochloride Extended-Release Tablets (LY03005), at the 19thNational Psychiatry Conference of the Chinese Medical Association.

Key Points: 
  • CHONGQING, China, Dec. 23, 2021 /PRNewswire/ --Luye Pharma Group today released the encouraging top-line results from a Phase II clinical trial of its new antidepressant, Ansofaxine Hydrochloride Extended-Release Tablets (LY03005), at the 19thNational Psychiatry Conference of the Chinese Medical Association.
  • In general, LY03005 demonstrated a comprehensive antidepressant efficacy as well as a good safety profile and tolerance based on the initial results of the Phase II clinical trial.
  • The drug has completed Phase I to Phase III clinical trials and is currently in the New Drug Application (NDA) phase in China.
  • In addition to China, LY03005 is also undergoing NDA phase in the U.S., and has completed Phase I clinical trials in Japan.

RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment

Retrieved on: 
Friday, December 3, 2021
Patient, News, HER2, CEO, Degenerative disease, Cancer, Environment, Disease, FISH, Drug discovery, GC, Autoimmune disease, B-cell activating factor, Diagnosis, Social conditions in Honduras, Health, Prevalence, IND, Solution, Laboratory, Breast cancer, Nature, Department, Immunology, Phase II, Cytokine, Treatment, Frost & Sullivan, UC, Research, Disability, Glucocorticoid, Stomach cancer, Marketing, National Medical Products Administration, ADC, Medicine in China, Mortality, III, NRDL, Peking Union Medical College Hospital, Stomach, Drug development, NMPA, SLE, Squamous cell carcinoma, Vaccine, Pharmaceutical industry

There is a substantial unmet medical need for more effective and better-tolerated therapies for the treatment of SLE.

Key Points: 
  • There is a substantial unmet medical need for more effective and better-tolerated therapies for the treatment of SLE.
  • Disitamab Vedotin is China's first domestically made antibody-drug conjugate indicated for HER2-expressing locally advanced or metastatic gastric cancer.
  • According to Frost & Sullivan, gastric cancer is one of the leading causes of cancer deaths globally.
  • The company is implementing a differentiated development and commercial strategy for Disitamab Vedotin, including: (i) gastric cancer (GC), (ii) urothelial carcinoma (UC), (iii) breast cancer (BC), and (iv) other HER2-expressing cancer.

Sustained Hepatitis B Surface Antigen Loss in Chronic Hepatitis B Patients with Subcutaneous PD-L1 Antibody ASC22 Treatment: Interim Results of Phase IIb Study

Retrieved on: 
Tuesday, November 9, 2021
Phase, Safety, Hong Kong Stock Exchange, PD-L1, American Association, Time, CDC classification system for HIV infection, HIV/AIDS, CHB, Infection, R, Cornerstone, Hepatitis C, HBsAg, CEO, IDE, Gannex, FXR, GBM, RESULTS, Society, AASLD, Nas, Institute of Liver and Biliary Sciences, Liver cancer, Immunotherapy, FASN, PD-1, Association, Liver, OBI Pharma, Inc., PBC, NASH, Degenerative disease, Hepatitis B virus, Late, American Association for Cancer Research, PLUS, Acne, HKEX, Society of Infectious Diseases Pharmacists, THR, Patient, Attention, Medicine in China, Pegasys, Medical device, Pharmaceutical industry, Vaccine

"ASC22 is the earliest and most advanced clinical stage immunotherapy in the world for CHB functional cure, i.e.

Key Points: 
  • "ASC22 is the earliest and most advanced clinical stage immunotherapy in the world for CHB functional cure, i.e.
  • Been selected for oral Late Breaking presentation indicates close attention by the committee of The Liver Meeting 2021 to the study."
  • We are excited to see ASC22 as an immunotherapy play a fundamental role in functional cure of CHB patients.
  • The percentage of patients with baseline HBsAg lower than 500 IU/mL is as high as 30% of all CHB patients.

Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients

Retrieved on: 
Wednesday, October 27, 2021
HIV, AIDS, Diagnosis, Aiken Regional Medical Center, Goal, ART, European, Patient, EACS, DDI, Medicine in China, Conference, Kidney, Immunity, Insurance, Global Vision, Subclinical infection, National Medical Products Administration, Health, HIV/AIDS, National List, Hospital, European AIDS Clinical Society, Intellectual property, ABT, ARts, Toxicity, Liver, Department, Viral load, Vaccine, Pharmaceutical industry, Fine chemical

Dr Dong Xie, Chief Scientific Officer, Chairman, Frontier Biotechnologiessaid, "We are honored to present at EACS and contribute to knowledge-building in the field of HIV/AIDS treatment.

Key Points: 
  • Dr Dong Xie, Chief Scientific Officer, Chairman, Frontier Biotechnologiessaid, "We are honored to present at EACS and contribute to knowledge-building in the field of HIV/AIDS treatment.
  • Critically-ill hospitalized AIDS patients represent an important and difficult to treat patient group.
  • Currently there is limited data on antiviral therapy for hospitalized AIDS patients with complicated opportunistic infections.
  • Founded in 2013, Frontier Biotechnologies Inc. ("Frontier Biotech") is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness.